Journal of Bacteriology, February 1999, p. 1343-1347, Vol. 181, No. 4
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Cloning and Characterization of Arylamine
N-Acetyltransferase Genes from Mycobacterium
smegmatis and Mycobacterium tuberculosis: Increased
Expression Results in Isoniazid Resistance
Mark
Payton,1
Roy
Auty,1
Rupika
Delgoda,1
Martin
Everett,2 and
Edith
Sim1,*
Department of Pharmacology, University of
Oxford, Oxford OX1 3QT,1 and
Research
and Development, Glaxo-Wellcome plc, Stevenage, Hertfordshire SG1
2NY,2 United Kingdom
Received 9 September 1998/Accepted 3 December 1998
 |
ABSTRACT |
Arylamine N-acetyltransferases (NATs) are found in many
eukaryotic organisms, including humans, and have previously been
identified in the prokaryote Salmonella typhimurium. NATs
from many sources acetylate the antitubercular drug isoniazid and so
inactivate it. nat genes were cloned from
Mycobacterium smegmatis and Mycobacterium tuberculosis, and expressed in Escherichia coli and
M. smegmatis. The induced M. smegmatis NAT
catalyzes the acetylation of isoniazid. A monospecific antiserum raised
against pure NAT from S. typhimurium recognizes NAT from
M. smegmatis and cross-reacts with recombinant NAT from
M. tuberculosis. Overexpression of mycobacterial
nat genes in E. coli results in predominantly
insoluble recombinant protein; however, with M. smegmatis
as the host using the vector pACE-1, NAT proteins from M. tuberculosis and M. smegmatis are soluble. M. smegmatis transformants induced to express the M. tuberculosis nat gene in culture demonstrated a threefold higher resistance to isoniazid. We propose that NAT in mycobacteria could have
a role in acetylating, and hence inactivating, isoniazid.
 |
TEXT |
Arylamine
N-acetyltransferases (NATs) are cytosolic enzymes which
acetylate arylamines and hydrazines by transfer of the acetyl group
from acetyl coenzyme A to the free amino group forming an acetylamide
(33). The same enzymes are also able to catalyze the
transfer of an acetyl group to the oxygen of an arylhydroxylamine (10, 32). NAT is widespread among eukaryotes (28,
33), and the existence of NAT in prokaryotes was, until recently,
thought to be confined to Salmonella typhimurium
(32). S. typhimurium NAT has the ability to
N-acetylate arylamines and the hydrazine isoniazid (24,
32). In humans there are now known to be two isoenzymes, NAT1 and
NAT2 (2). The human enzyme NAT2, whose substrates include
sulfonamide-based antibacterial compounds (20), was first
identified as the enzyme which inactivates the front-line antitubercular drug isoniazid (9). The sulfonamides
sulfamethoxazole and p-aminosalicylate are acetylated
predominantly by the human isoenzyme NAT1 (4, 13), as is
p-aminobenzoic acid (18, 30). Both NAT1 (22,
34) and NAT2 (for a review, see reference 5)
show polymorphism in human populations. Identification of human NAT2
polymorphisms provides an explanation for the different effective
therapeutic doses of isoniazid in fast and slow acetylators (8,
9).
We report here the cloning of the nat genes from the
eubacteria Mycobacterium smegmatis and Mycobacterium
tuberculosis and show that the M. smegmatis NAT is
active with a range of substrates, including isoniazid. We demonstrate,
using antibodies raised against recombinant S. typhimurium
NAT, that NAT is present in wild-type M. smegmatis. It was
reasoned that if isoniazid was acetylated by NAT prior to activation,
an elevated resistance to isoniazid would be observed if more NAT were
present in M. smegmatis. We therefore expressed the M. tuberculosis nat gene in M. smegmatis using the shuttle
vector pACE-1 (21) and observed the effect of induction of
NAT protein on the growth of mycobacteria cultured in isoniazid.
Identification of nat genes in M. smegmatis
and M. tuberculosis.
A radiolabelled DNA probe representing
a 264-bp HindIII fragment of S. typhimurium
nat (32), corresponding to a region which spans two
highly conserved areas in NAT, was used to isolate clones containing
nat from M. smegmatis and M. tuberculosis (strain H37Rv). Gridded libraries containing at least
two copies of the M. smegmatis and M. tuberculosis genomes were screened, and double positives were
selected. All sequence analyses were performed by an automated (ABI
377) sequencer (The Advanced Biotechnology Centre, ICSM, London) with
Fidelase, an enzyme suitable for regions rich in GC. Amino acid
sequences representing putative open reading frames of M. smegmatis and M. tuberculosis NAT are illustrated in
Fig. 1 together with a PILEUP comparison
of known NAT amino acid sequences. The sequence of M. tuberculosis NAT corresponds exactly to the sequence deposited
previously in the database (3), assigned as a hypothetical
protein. NAT from the genome of Escherichia coli is also
shown for comparison and was obtained by database searching, again
assigned as a hypothetical protein (1). These sequences are
illustrated in order to emphasize the common features in all NAT
proteins; the conserved PFENL and RGGDC sequences (where D is either W
or Y), containing the active-site cysteine and the arginine residues
proposed to participate in the reaction mechanism (6, 32),
are indicated in Fig. 1. The M. smegmatis nat gene open
reading frame is >60% identical to M. tuberculosis nat,
and these genes have GC contents of 69 and 65%, respectively,
compatible with the genes being of mycobacterial origin
(15). The mycobacterial NATs each show amino acid sequence
identities of ~35 and 30% with the NATs from S. typhimurium and human NAT2, respectively (Fig. 1).

View larger version (117K):
[in this window]
[in a new window]
|
FIG. 1.
Amino acid alignment of the predicted M. smegmatis and M. tuberculosis NAT against NAT
homologues of eukaryotic and prokaryotic origins. Amino acids are
represented by the single-letter code. Numbers refer to amino acid
positions of the aligned sequences, which are ranked in order of
decreasing similarity in comparison with human NAT1. Codes on the left
identify the relevant NAT sequence. Human(1) is human NAT1, accession
no. P18440; Human(2) is human NAT2, accession no. P11245; Hamster(1) is
hamster NAT1, accession no. P50292; Mouse(1) is mouse NAT1, accession
no. P50294; Hamster(2) is hamster NAT2, accession no. P50293; Mouse(2)
is mouse NAT2, accession no. P50295; E. coli is E. coli NAT,
accession no. P77567; S. typhimurium is S. typhimurium NAT,
accession no. Q00267; M. tuberculosis is M. tuberculosis
NAT, accession no. P96848, which codes for a hypothetical protein
(3) and has the same sequence as the M. tuberculosis NAT described in this report; and M. smegmatis is
M. smegmatis NAT, accession no. AJ006588. Amino acids
showing identity in all NATs are shown in white on a black background,
while residues showing conservation and similarity in more than four
species of NAT are indicated in white on a grey background. A dot
represents a gap introduced to maximize homology. The proposed active
site cysteine is indicated (§) (32), as are the arginine
residues thought to participate in the reaction ( ) (6,
32). Regions of complete identity are underscored.
|
|
Expression of mycobacterial nat genes in E. coli.
The predicted open reading frames of S. typhimurium, M. smegmatis, and M. tuberculosis
nat genes were cloned into the expression vector pET28b (Novagen).
E. coli cells (DE23-pLysS) were transformed with the
constructs for recombinant protein production, which also encode a
2.1-kDa thrombin-cleavable N-terminal histidine tag.
Recombinant protein production was carried out as described previously
(24). E. coli cells were disrupted by sonication on ice, eight times each for 30 s with 15-s intervals between sonications, and centrifuged at 100,000 × g for 60 min
at 4°C. Supernatant was removed, and the pellet was resuspended in an equal volume of resuspension buffer (50 mM Tris-HCl [pH 8.0], 2 mM
EDTA, 4 mM dithiothreitol, and 1 mM Pefabloc [protease inhibitor]). It was demonstrated that the nat sequence from M. smegmatis induces the synthesis of a protein of ~32 kDa, close
to the predicted size of 32.3 kDa, corresponding to the open reading
frame coding for the NAT protein (275 amino acids) plus the
hexahistidine fusion tag (2.1 kDa). The recombinant NAT protein from
M. smegmatis was found associated predominantly with the
insoluble pellet (Fig. 2A, lane 4). The
molecular mass of the M. tuberculosis NAT protein (275 amino
acids) plus the hexahistidine tag is predicted to be 33.5 kDa. The NAT
recombinant protein of M. tuberculosis has a molecular mass
of around 32 kDa and is found exclusively in the insoluble pellet when
produced in E. coli (Fig. 2A, lane 2). The molecular mass of
the S. typhimurium NAT protein (283 amino acids) with the
hexahistidine tag is predicted to be 34.3 kDa and is found
predominantly in the soluble, supernatant fraction (Fig. 2A, lane 3).

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 2.
Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis analysis of recombinant NAT proteins in E. coli. (A) Gels were stained with Coomassie blue. E. coli cells were transformed with pET28b alone (lanes 1) or with
pET28b constructs containing the coding region of nat from
M. tuberculosis (lanes 2), S. typhimurium (lanes
3), or M. smegmatis (lanes 4). Lysates were used to generate
supernatants (S) and pellets resuspended in the original volume of
lysate (P). Individual lanes were loaded with 15 µl of each fraction.
The upper and lower arrows indicate the migration of recombinant
S. typhimurium and mycobacterial NATs, respectively. Lane M,
molecular mass markers. (B) Western blot analysis using an antiserum
(1:100,000) against recombinant S. typhimurium NAT developed
by using an enhanced chemiluminescence detection system
(27). Lane 1, supernatant from E. coli
transformed with pET28b alone; lane 2, pellet from E. coli
transformed with M. tuberculosis NAT; lane 3, supernatant
from E. coli transformed with S. typhimurium NAT;
lane 4, supernatant from E. coli transformed with M. smegmatis NAT.
|
|
An antiserum raised against purified recombinant S. typhimurium NAT (24) was used to confirm the identity
of the induced protein bands observed in Fig. 2A. The immunization
schedule and detection were carried out as previously described
(27). The antiserum was used at a dilution of 1:100,000 and
did not cross-react with the control E. coli supernatant
that had been transformed with vector alone under the conditions used
(Fig. 2B, lane 1). The antiserum does identify a low level of
endogenous E. coli NAT when used at a dilution of 1:50,000
(data not shown). The antiserum, at 1:100,000, cross-reacted with a
strong band in the supernatant of E. coli transformed with
nat from S. typhimurium (Fig. 2B, lane 3) and in
the supernatant of E. coli which had been transformed with
the putative nat from M. smegmatis (Fig. 2B, lane
4). No band corresponding to M. tuberculosis NAT was found
in the supernatant fraction (data not shown). However, a protein in the
pellet fraction of E. coli cells expressing the M. tuberculosis nat gene was shown to cross-react with the antiserum to S. typhimurium NAT. The degree of recognition of the NAT
from M. tuberculosis in the pellet (Fig. 2B, lane 2) is less
than that expected based on the protein staining intensity (Fig. 2A,
lane 2P), suggesting that the antiserum to the S. typhimurium NAT cross-reacts less with the M. tuberculosis protein than with the M. smegmatis protein
(Fig. 2A, lane 4S, and Fig. 2B, lane 4).
The detection of NAT activity using the arylamines anisidine,
4-aminoveratrole, and p-aminobenzoic acid was carried out by a colorimetric assay (24), and activity with the hydrazine
isoniazid was detected by the method of Olson et al. (19).
Bacterial lysates and supernatants were diluted up to 50-fold with 20 mM Tris-HCl (pH 7.5) and 2 mM dithiothreitol before being used.
Controls were carried out with identically diluted samples of E. coli cell lysate fractions that had been transformed with pET28b
alone and demonstrated no activity under the conditions used. Likewise,
insoluble pellets from E. coli cells expressing the M. tuberculosis nat gene or the M. smegmatis nat gene had
no NAT enzymic activity. It was concluded that the NAT protein in these
pellets was in inclusion bodies. Recombinant NAT from M. smegmatis in the supernatant fraction of E. coli is
active in acetylating a series of substrates, including isoniazid,
anisidine, and 4-aminoveratrole, which are also substrates of the
S. typhimurium enzyme. The arylamine
p-aminobenzoic acid is poorly acetylated by NAT from both
M. smegmatis and S. typhimurium (24).
Isoniazid is a better substrate (Km, 25 µM;
Vmax/Km 2,520 × 10
6 liter · min
1 · mg of
protein
1) than are the arylamines anisidine
(Km, 300 µM;
Vmax/Km, 16 × 10
6 liter · min
1 · mg of
protein
1) and 4-aminoveratrole (Km,
650 µM; Vmax/Km, 25 × 10
6 liter · min
1 · mg of
protein
1) for the NAT enzyme from M. smegmatis. These results suggest the enzyme has a substrate
specificity similar to that of the S. typhimurium enzyme
(24, 32).
Expression of mycobacterial nat genes in M. smegmatis.
M. smegmatis and M. tuberculosis nat
genes were also expressed by using the mycobacterial expression vector
pACE-1. Competent M. smegmatis cells (Mc2155
[26]) were electroporated with 1 µg of plasmid DNA,
either alone or containing the nat insert, at 700
, 2.5 kV, and 25 µF (26). M. smegmatis cells were
grown on the selective medium 7H9 supplemented with
albumin-dextrose-catalase (Difco) or 7H11 agar supplemented with oleic
acid-albumin-dextrose-catalase (Difco) containing hygromycin (50 µg/ml). Minimal medium was used for gene expression using the pACE-1
constructs (21). These constructs yield recombinant protein
when acetamide (2 mg/ml) is supplied as the sole carbon source in the
growth medium. M. smegmatis cell pellets were sonicated on
ice 10 times, each for 1 min, with 30-s intervals between sonications.
The resulting cell lysates were centrifuged at 100,000 × g for 60 min at 4°C. Supernatants were kept, and the pellets
were resuspended to the original volume in resuspension buffer. With
this expression vector, recombinant mycobacterial NAT protein was
detected predominantly in the supernatant fraction (Fig.
3A). Cells expressing the M. smegmatis nat (Fig. 3A, lane 4) routinely had more recombinant
protein than the cells expressing the M. tuberculosis nat
gene (Fig. 3A, lanes 2 and 3). The sizes of the induced protein bands
were around 30 kDa, which corresponds to the expected sizes for NAT
proteins without a hexahistidine tag. The antiserum raised against the
pure S. typhimurium NAT identified a band in the
supernatants of M. smegmatis induced to express the M. smegmatis nat gene (Fig. 3B and C, lane 4) and, with longer
exposure of the autoradiograph, the presence of M. tuberculosis NAT (Fig. 3C, lanes 2 and 3). There was also an
indication of endogenous NAT (Fig. 3C, lane 1). The sizes of the
endogenous and induced proteins (which have no hexahistidine tags)
illustrated in Fig. 3 are indistinguishable, as expected. An antiserum
raised against recombinant M. tuberculosis NAT, prepared by
immunizing rabbits with insoluble recombinant protein excised from a
polyacrylamide gel slice, was used at a dilution of 1:100,000 and is
highly specific for M. tuberculosis NAT (Fig. 3D, lanes 2 and 3). It does not recognize M. smegmatis NAT under the
conditions shown in Fig. 3D.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 3.
Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis analysis of recombinant NAT proteins in M. smegmatis. Gels were loaded with 15 µl of supernatants from
lysates of M. smegmatis transformed with pACE-1 alone (lane
1), with M. tuberculosis nat (lanes 2 and 3), or with
M. smegmatis nat (lane 4) (M, molecular mass markers [in
kilodaltons]). (A) Staining with Coomassie blue. The arrow indicates
the additional band in the supernatants transformed with a
nat gene. (B to D) Western blots developed by using an
enhanced chemiluminescence detection system as described previously
(27), where exposure time for detection of the second
antibody is either 1 min (B and D) or 20 min (C). In each panel, lane 1 has been loaded with 10 µg of total protein and lanes 2 to 4 have
been loaded with 600 ng of total protein. An antiserum raised against
recombinant M. tuberculosis NAT protein synthesized in
E. coli is shown in panel D. The antiserum used in panels B
and C is the antiserum against pure S. typhimurium NAT
(24). Both antisera were used at a dilution of 1:100,000.
|
|
Overproduction of mycobacterial nat genes in M. smegmatis results in increased resistance to isoniazid.
We
have investigated whether the expression of the nat gene
from M. tuberculosis alters the sensitivity of M. smegmatis to isoniazid in vivo. M. smegmatis
transformants of pACE-1 either alone or containing the nat
gene from M. tuberculosis were grown in minimal medium
containing either acetamide to induce synthesis of protein or an
equivalent carbon concentration of glucose which does not induce
protein synthesis from the pACE-1 vector. Cultures were grown for up to
48 h in the presence of different amounts of isoniazid, and cell
growth was determined at 600 nm with a plate reader (Titertek
Multiskan). It was observed that when the expression of the
nat gene was induced, there was an increase in the
concentration of isoniazid in the growth medium that could be tolerated
(Fig. 4). There was no change in the
response to isoniazid in M. smegmatis cultures containing
the nat gene construct when the growth conditions did not
induce synthesis of recombinant NAT protein. In contrast, M. smegmatis cells, which contained only vector, were equally
sensitive to isoniazid, irrespective of whether acetamide or glucose
was the carbon source.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of expression of M. tuberculosis nat
on the growth of M. smegmatis in the presence of isoniazid
(INH). Results for cultures of M. smegmatis either
transformed with pACE-1 alone (open circles) or with pACE-1 containing
M. tuberculosis nat (solid circles) grown in minimal medium
containing acetamide and cultures of pACE-1 containing M. tuberculosis nat grown in minimal medium containing glucose
(triangles) are shown.
|
|
Discussion.
The existence of highly conserved arylamine
N-acetyltransferase sequences in bacteria other than
S. typhimurium suggests that the enzyme is conserved in
evolution. The role of NAT in endogenous metabolism is unclear,
although it has been suggested that in eukaryotes, NAT (in particular,
the human NAT1 isoenzyme) plays a role in folate catabolism (16,
31). The very poor activity of the NAT from M. smegmatis or S. typhimurium with
p-aminobenzoic acid can be rationalized on the basis that a
supply of p-aminobenzoic acid is essential for folate
synthesis in prokaryotes. The activity profile is more like that of the
human isoenzyme NAT2 which is responsible for the inactivation, by
acetylation, of isoniazid (18). NATs are present in several
bacterial species, and a sequence similar to NAT has been identified in
the completed genome sequence of E. coli (1). It
has been demonstrated in the present study that the activity in
E. coli with all substrates tested is less than 1% of the
activity of the other recombinant NATs overproduced in E. coli. In addition to the overall homology, alignment of NAT
sequences (Fig. 1) necessitates the introduction, in the bacterial sequences, of a gap of around 20 amino acids on the C-terminal region
flanking the N- and C-terminal regions of the molecule (12).
It has been suggested that the N-terminal region is predominantly alpha
helix, while the C-terminal portion is predominantly beta sheet. The
gap corresponds to the region linking these two secondary structure
domains of the molecule. The bacterial NAT enzymes appear to be
particularly stable to proteolysis, in contrast to the mammalian NAT
enzymes (25), which may be due to the lack of a randomly structured loop in the bacterial NATS.
The expression of NAT in mycobacteria has important implications.
Mycobacteria are exquisitely sensitive to isoniazid (14), although there are differences among the mycobacteria in their levels
of sensitivity to the drug. M. tuberculosis will not grow in
0.2 µg of isoniazid per ml (21), and M. smegmatis will not grow in 5 µg of isoniazid per ml
(7). When we induced the synthesis of more NAT in M. smegmatis, growth of the mycobacteria was not arrested until the
concentration of isoniazid was 15 µg/ml. Isoniazid is inactivated in
humans through acetylation (8, 9). The results presented
here demonstrate that NAT is expressed endogenously in M. smegmatis and that the NAT proteins from mycobacteria can acetylate isoniazid and thus appear able to inactivate isoniazid in
vivo. There is a body of evidence to demonstrate that the
antimycobacterial activity of isoniazid in mycobacteria relies on the
drug first becoming activated (11, 17, 23). It is already
known that the acetylation of isoniazid inactivates the drug. The
results presented here support the concept that the acetylation of
isoniazid in mycobacteria acts in competition with the activation
through oxidation. It is therefore important to investigate
nat expression in other mycobacteria, including particularly
M. tuberculosis, in which development of isoniazid
resistance cannot be accounted for completely by currently identified
loci (29).
 |
ACKNOWLEDGMENTS |
We are extremely grateful to the Wellcome Trust for financial support.
We thank S. Martin for the preparation of the gridded libraries and D. Young, K. Duncan, and J. Sinclair for very helpful discussions. We also
thank James Sandy for excellent technical assistance.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pharmacology, University of Oxford, Mansfield Rd., Oxford OX1 3QT,
United Kingdom. Phone: (44 1865) 271596. Fax: (44 1865) 271853. E-mail: esim{at}worf.molbiol.ox.ac.uk.
 |
REFERENCES |
| 1.
|
Blattner, F.,
G. Plunkett,
C. Bloch,
N. Perna,
V. Burland,
M. Riley,
J. Collado-Vides,
J. Glasner,
C. Rode,
G. Mayhew,
J. Gregor,
N. Davis,
H. Kirkpatrick,
M. Goeden,
D. Rose,
B. Mau, and Y. Shao.
1997.
The complete genome sequence of Escherichia coli K12.
Science
277:1453-1474[Abstract/Free Full Text].
|
| 2.
|
Blum, M.,
D. M. Grant,
W. McBride,
M. Heim, and U. A. Meyer.
1990.
Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression.
DNA Cell Biol.
9:193-203[Medline].
|
| 3.
|
Cole, S. T.,
R. Brosch,
J. Parkhill,
T. Garnier,
C. Churcher,
D. Harris, and B. Barrel.
1998.
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.
Nature
393:537-544[Medline].
|
| 4.
|
Cribb, A. E.,
H. Nakamura,
D. M. Grant,
M. A. Miller, and S. P. Spielberg.
1993.
Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism.
Biochem. Pharmacol.
45:1277-1282[Medline].
|
| 5.
|
Deguchi, T.
1992.
Physiology and molecular biology of arylamine N-acetyltransferases.
Biomed. Res.
13:231-242.
|
| 6.
|
Delomenie, C.,
G. H. Goodfellow,
R. Krishnamoorthy,
D. M. Grant, and J. M. Dupret.
1997.
Study of the role of the highly conserved residues Arg(9) and Arg(64) in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis.
Biochem. J.
323:207-215.
|
| 7.
|
Dhandayuthapani, S.,
Y. Zhang,
M. H. Mudd, and V. Deretic.
1996.
Oxidadtive stress response and its role in sensitivity to isoniazid in mycobacteria: characterization and inducibility of ahpC by peroxides in Mycobacterium smegmatis and lack of expression in M. aurum and M. tuberculosis.
J. Bacteriol.
178:3641-3649[Abstract/Free Full Text].
|
| 8.
|
Ellard, G. A., and P. T. Gammon.
1976.
Pharmacokenetics of isoniazid metabolism in man.
J. Pharmacokinet. Biopharm.
4:83-113[Medline].
|
| 9.
|
Evans, D. A. P.,
K. A. Manley, and V. A. McKuisick.
1960.
Genetic control of isoniazid acetylation in man.
Br. Med. J.
2:485-491.
|
| 10.
|
Hein, D. W.,
M. A. Doll,
K. Gray,
T. D. Rustan, and R. J. Ferguson.
1993.
Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
Cancer Res.
53:509-514[Abstract/Free Full Text].
|
| 11.
|
Heym, B.,
Y. Zhang,
S. Poulet,
D. Young, and S. T. Cole.
1993.
Characterization of the katG gene encoding catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis.
J. Bacteriol.
175:4255-4259[Abstract/Free Full Text].
|
| 12.
|
Hubbard, T.,
A. Tramontano, and I. W. Team.
1996.
Update on protein structure prediction: results of the 1995 IRBM Workshop.
Protein Folding Design
1:R55-R63.
|
| 13.
|
Jehne, J. W.
1965.
Partial purification and properties of the isoniazid transacetylase in human liver: its relationship to the acetylation of p-aminosalicylic acid.
J. Clin. Investig.
44:1992-2002.
|
| 14.
|
Kruger-Thiemer, E.
1958.
Isonicotinic acid hypothesis of the anti-tuberculosis action of isoniazid.
Am. Rev. Tuberc.
78:364-367.
|
| 15.
|
Lévy-Frébault, V. V., and F. Portaels.
1992.
Proposed minimum standards for the genus Mycobacterium and for description of new slowly growing Mycobacterium species.
Int. J. Syst. Bacteriol.
42:315-323[Medline].
|
| 16.
|
Minchin, R. F.
1995.
Acetylation of para-aminobenzoylglutamate, a folate catabolite, by recombinant human NAT and U937 cells.
Biochem. J.
307:1-3.
|
| 17.
|
Musser, M.,
V. Kapur,
D. Williams,
B. Kreiswirth,
D. van Soolingen, and J. Van Embden.
1996.
Characterisation of the catalase-peroxidase gene (katG) and inhA locus in isoniazid resistant and susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance.
J. Infect. Dis.
173:196-202[Medline].
|
| 18.
|
Ohsako, S., and T. Deguchi.
1990.
Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases of human liver.
J. Biol. Chem.
265:4630-4634[Abstract/Free Full Text].
|
| 19.
|
Olson, W.,
P. Dayton,
Z. Israili, and A. Pruitt.
1977.
Spectrophotofluorimetric assay for isoniazid and acetylisoniazid in plasma adapted to paediatric studies.
Clin. Chem.
23/24:745-748.
|
| 20.
|
Palamanda, J.,
D. Hickman,
A. Ward,
E. Sim,
M. Romkes-Sparks, and J. Unadkat.
1995.
Dapsone acetylation by human liver N-acetyltransferase and interaction with anti-opportunistic infection drugs.
Drug Metab. Dispos.
23:473-477[Abstract].
|
| 21.
|
Parish, T.,
E. Mahenthiralingam,
P. Draper,
E. O. Davis, and M. J. Colston.
1997.
Regulation of the inducible amidase gene of Mycobacterium smegmatis.
Microbiology
143:2267-2276[Abstract].
|
| 22.
|
Risch, A.,
V. Smelt,
D. Lane,
L. Stanely,
W. van der Slot,
A. Ward, and E. Sim.
1996.
Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients.
Pharmacol. Toxicol.
78:235-240[Medline].
|
| 23.
|
Rozwarski, D. A.,
G. A. Grant,
D. H. R. Barton,
W. R. Jacobs, and J. C. Sacchettini.
1998.
Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Science
279:98-102[Abstract/Free Full Text].
|
| 24.
|
Sinclair, J.,
R. Delgoda,
M. Noble,
S. Jarmin,
N. Goh, and E. Sim.
1998.
Purification, characterisation and crystallisation of an N-hydroxyarylamine O-acetyltransferase from Salmonella typhimurium.
Prot. Expr. Purif.
12:371-380[Medline].
|
| 25.
|
Sinclair, J., and E. Sim.
1997.
A fragment consisting of the first 204 amino-terminal amino acids of human arylamine N-acetyl transferase one (NAT1) and the first transacetylation step of catalysis.
Biochem. Pharmacol.
53:11-16[Medline].
|
| 26.
|
Snapper, S. B.,
R. E. Melton,
S. Mustafa,
T. Kieser, and W. R. Jacobs.
1990.
Isolation and characterisation of efficient plasmid transformation mutants of Mycobacterium smegmatis.
Mol. Microbiol.
4:1911-1919[Medline].
|
| 27.
|
Stanley, L.,
I. Mills, and E. Sim.
1997.
Localisation of polymorphic N-acetyltransferase (NAT2) in tissues of inbred mice.
Pharmacogenetics
7:121-130[Medline].
|
| 28.
|
Vatsis, K. P.,
W. W. Weber,
D. A. Bell,
J. M. Dupret,
D. A. Evans,
D. M. Grant,
D. W. Hein,
H. J. Lin,
U. A. Meyer,
M. V. Relling, et al.
1995.
Nomenclature for N-acetyltransferases.
Pharmacogenetics
5:1-17[Medline].
|
| 29.
|
Victor, T. C.,
R. Warren,
J. L. Butt,
A. M. Jordaan,
J. V. Felix,
A. Venter,
F. A. Sirgel,
H. S. Schaaf,
P. R. Donald,
M. Richardson,
M. H. Cynamon, and P. D. VanHelden.
1997.
Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis.
J. Med. Microbiol.
46:847-857[Abstract].
|
| 30.
|
Ward, A.,
D. Hickman,
J. W. Gordon, and E. Sim.
1992.
Arylamine N-acetyltransferase in human red blood cells.
Biochem. Pharmacol.
44:1099-1104[Medline].
|
| 31.
|
Ward, A.,
M. Summers, and E. Sim.
1995.
Purification of recombinant human NAT1 expressed in E. coli.
Biochem. Pharm.
49:1759-1767[Medline].
|
| 32.
|
Watanabe, M.,
T. Sofuni, and T. Nohmi.
1992.
Involvement of Cys69 residue in the catalytic mechanism of N-hydroxyarylamine O-acetyltransferase of Salmonella typhimurium. Sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferase for S. typhimurium and higher organisms.
J. Biol. Chem.
267:8429-8436[Abstract/Free Full Text].
|
| 33.
|
Weber, W. W., and D. W. Hein.
1985.
Arylamine N-acetyltransferases.
Pharmacol. Rev.
37:25-79[Medline].
|
| 34.
|
Weber, W. W., and K. P. Vatsis.
1993.
Individual variability in p-aminobenzoic acid acetylation by human N-acetyltransferase (NAT1) of peripheral blood.
Pharmacogenetics
3:209-212[Medline].
|
Journal of Bacteriology, February 1999, p. 1343-1347, Vol. 181, No. 4
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.